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SERPINB2 is a novel TGFβ-
responsive lineage fate 
determinant of human bone 
marrow stromal cells
Mona Elsafadi1,2, Muthurangan Manikandan1, Muhammad Atteya1,3, Raed Abu Dawud4,5, 
Sami Almalki6, Zahid Ali Kaimkhani1, Abdullah Aldahmash1,7, Nehad M. Alajez1, Musaad 
Alfayez1, Moustapha Kassem1,2 & Amer Mahmood1
TGF-β1, a multifunctional regulator of cell growth and differentiation, is the most abundant bone 
matrix growth factor. During differentiation of human bone stromal cells (hBMSCs), which constitute 
bone marrow osteoblast (OS) and adipocyte (AD) progenitor cells, continuous TGF-β1 (10 ng/ml) 
treatment enhanced OS differentiation as evidenced by increased mineralised matrix production. 
Conversely, pulsed TGF-β1 administration during the commitment phase increased mature lipid-filled 
adipocyte numbers. Global gene expression analysis using DNA microarrays in hBMSCs treated with 
TGF-β1 identified 1587 up- and 1716 down-regulated genes in OS-induced, TGF-β1-treated compared to 
OS-induced hBMSCs (2.0 fold change (FC), p < 0.05). Gene ontology (GO) analysis revealed enrichment 
in ‘osteoblast differentiation’ and ‘skeletal system development-associated’ genes and up-regulation 
of several genes involved in ‘osteoblastic-differentiation related signalling pathways’. In AD-induced, 
TGF-β1-treated compared to AD-induced hBMSCs, we identified 323 up- and 369 down-regulated genes 
(2.0 FC, p < 0.05) associated with ‘fat cell differentiation’, ‘fatty acid derivative biosynthesis process’, 
‘fatty acid derivative metabolic process’, and ‘inositol lipid-mediated’. Serpin peptidase inhibitor, clade 
B (ovalbumin), member 2 (SERPINB2) was down-regulated 3-fold in TGF-β1-treated hBMSCs. siRNA-
mediated SERPINB2 inhibition enhanced OS and AD differentiation. Thus, TGF-β signalling is important 
for hBMSC OS and AD differentiation and SERPINB2 is a TGF-β-responsive gene that plays a negative 
regulatory role in hBMSC differentiation.
Skeletal stem cells (also known as bone marrow-derived multipotent stromal cells or bone marrow mesenchymal 
stem cells (BMSC)) comprise multipotent stem cells that can differentiate into adipocytes (ADs or osteoblasts 
(OS) in response to micro-environmental signals including growth factors, cytokines, and epigenetic regula-
tors1. An imbalance between OS and AD lineage commitment and differentiation has been implicated as a cause 
for age-related impaired bone formation; thus, a number of therapeutic interventions have been proposed for 
enhancing bone mass through the targeting of BMSC2, 3.
TGF-β1 constitutes one of the most abundant growth factor in the bone matrix (200 μg/kg)4 and is secreted by 
several cells associated with the skeleton; e.g. OS, endothelial cells, smooth muscle cells, and stromal cells, as well 
as by cells of the immune system5. TGF-β1 is produced in large precursor complexes that are composed of mature 
TGF-β1 and latency-associated protein (LAP). TGF-β1 is secreted and deposited in bone matrix as an inactive, 
latent complex owing to its non-covalent linkage to LAP, which masks the receptor-domains of the active TGF-β1. 
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Osteoclast-mediated bone resorption activates TGF-β1 by cleavage of LAP and releases it from the bone matrix, 
creating a gradient of active TGF-β1 that signals to recruit osteoprogenitor cells to the bone remodelling sites and 
thus support bone formation6. TGF-β1 has been shown to regulate the proliferation and differentiation of osteo-
blastic cells7 and inhibition of TGF-β receptor signalling in OS has been reported to decrease bone remodelling 
and increase trabecular bone mass6.
In the current study, we examined the role of TGFβ-1 in OS and AD lineage commitment and the differenti-
ation of human BMSC (hBMSC) and the dependency of these effects on the timing of induction as determined 
using a single pulse dose during the commitment phase of hBMSC versus continuous treatment during the whole 
differentiation period. In addition, we examined the molecular mechanisms of TGFβ-1-mediated differentiation 
of hBMSCs employing DNA microarrays. We identified one of the significantly (3-fold) down-regulated genes 
during TGFβ1 stimulation, serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), as a novel 
TGF-β-responsive gene that plays a role in hBMSC differentiation. We demonstrated that inhibition of SERPINB2 
in hBMSC led to enhanced OS and AD differentiation suggesting a negative regulatory role in OS and AD differ-
entiation, downstream of TGF-β signalling.
Results
Continuous treatment with TGF-β1 enhances OS differentiation. We compared the effect on 
hBMSC differentiation to OS when TGFβ1 (10 ng/ml) treatment was conducted as a single pulse dose during 
the commitment phase of differentiation (day −2 to day 0) versus continuous treatment during the whole course 
of differentiation (day −2 to day 7) (Fig. 1A). As judged by qualitative and quantitative alizarin red staining for 
mineralised matrix formation, continuous treatment with TGF-β1 induced a higher degree of OS differentiation 
Figure 1. TGF-β1 promotes osteogenic differentiation. Human bone marrow stromal (skeletal) stem cells 
(hBMSC) were differentiated into osteoblasts (OS) using osteogenic induction mixture for 7 days. (A) Time line 
scheme of experimental setup illustrating TGF-β1 or SB-431542 (SB) treatment that was performed as either 
single pulse dose (TGFB1 1-dose or SB 1-dose) or continuous treatment (TGFB1 Contin. Or SB Contin.) at 
commitment and differentiation stages of in vitro OS differentiation (B) Mineralised calcium deposition was 
determined by Alizarin Red S staining, which is shown as microscopic images (20× magnification).  
(C) Alizarin Red Quantification under different experimental conditions: osteo-induced (OS), single dose of 
10 ng/ml TGF-β1 (+TGFB1); continuous exposure to TGF-β1, TGFB1 con, SB 1-dose, and SB Con. Data are 
presented as the means ± SD of three independent experiments; n = 6; (D) qRT-PCR of ALPL (left panel) or 
RUNX2 (right panel) mRNA expression preformed on cells exposed to the indicated treatment on days 1, 3, and 
7. Expression of each target gene was normalised to GAPDH. Data are presented as the means ± SD from three 
independent experiments, n = 6; *p < 0.05; **p < 0.01, ***p < 0.005.
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(Fig. 1B,C, p < 0.01). These effects represented direct effects of TGF-β1, as they were reduced following exposure 
to the TGFβ receptor kinase inhibitor SB-431542 (10 M). Quantitative reverse transcription-polymerase chain 
reaction (RT-PCR) was further performed to assess gene expression of osteoblastic markers upon continuous 
application of TGFβ-1. Gene expression of alkaline phosphatase, liver/bone/kidney (ALPL) exhibited significant 
up-regulation at day 3, whereas runt-related transcription factor 2 (RUNX2) showed gradual up-regulation starting 
from day 1 up to day 3 (Fig. 1D).
Single pulse treatment with TGFβ-1 enhances AD differentiation. We next compared the effect 
on hBMSC differentiation to AD when TGFβ1 (10 ng/ml) treatment was conducted as a single pulse dose dur-
ing the commitment phase of differentiation (day −2 to day 0) versus continuous treatment during the whole 
course of differentiation (day −2 to day 7) (Fig. 2A). As shown in Fig. 2A and B, qualitative and quantitative 
Nile red staining of mature adipocytes following single pulse treatment with TGFβ-1 led to a greater degree of 
AD differentiation enhancement compared with continuous treatment (Fig. 2B and C). SB-431542 treatment 
significantly reduced AD induction during continuous treatment and to a lesser degree in the single pulse dose. 
Gene expression analysis of the adipogenic markers lipoprotein lipase (LPL), peroxisome proliferator-activated 
receptor gamma 2 (PPARG2), and adiponectin or (ADIPOQ) exhibited similar effects (Fig. 2D–F).
Figure 2. TGF-β1 promotes adipogenic differentiation. (A) Time line schematic model illustrating the dose 
of TGF-β1 or SB-431542 (SB) treatment for either single pulse or continuous treatment at commitment 
and differentiation stages during adipogenic induction of human bone marrow stromal (skeletal) stem cells 
(hBMSC) (B) hBMSCs were induced into adipocyte using adipocyte induction medium in the presence of 
single dose (AD + TGFB1 1-dose) or continuous (AD + TGFB1 Contin.) exposure to 10 ng/ml TGF-β1 or a 
single (AD + SB 1-dose) or continuous (AD + SB Contin.) treatment with 10 µM SB-431542. Cells were stained 
on day 7 using oil red O staining for adipocytes containing lipid droplets, and shown as microscopic images 
(20×, magnification), non-induced (NI), adipocytic induced (AD). (C) Nile red quantification under the 
indicated treatment conditions was performed on day 7 post adipocyte induction. qRT-PCR quantification for 
LPL (D), PPARG2 (E), and ADIPOQ (F) mRNA under the indicated experimental conditions: non-induced 
(CNT), adipo-induced (AD), single dose of TGF-β1 (+TGFB1), continuous exposure to TGF-β1 (+TGFB1 
Contin.), single dose of SB-431542 (+SB), and continuous dose of SB-431542 (+SB Contin.). Expression of 
each target gene was normalised to GAPDH. Data are presented as the means ± SD from three independent 
experiments, n = 6; *p < 0.05; **p < 0.01, ***p < 0.005.
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Molecular phenotype of TGF-β1-induces osteoblastic cells. Global gene expression profiling was 
conducted on hBMSC treated with or without TGF-β1 (10 ng/ml) in the presence of OS induction medium. 
Hierarchical clustering based on differentially expressed genes revealed clear separation of control cells treated 
with OS induction medium alone (OS-differentiated) from those treated with TGF-βl (OS-differentiated-TGF-β1) 
(Fig. 3A). We identified 1587 up-regulated and 1716 down-regulated genes in OS-differentiated-TGF-β1 com-
pared to OS-differentiated control (2.0 fold change (FC), p < 0.05; Supplementary Tables S1, S2). Pathway analysis 
of the up-regulated genes revealed significant enrichment in several pathways related to ‘endochondral ossifica-
tion’, ‘matrix metalloproteinases’, ‘TGF-β signalling’, ‘WNT signalling’, ‘MAPK signalling’, ‘focal adhesion’, and’ 
regulation of actin cytoskeleton pathways’ (Fig. 3B, Supplementary Figs S1–S7). Table 1 lists the matched enti-
ties from the microarray data and the corresponding signalling pathway. Comparing the up-regulated genes 
in OS-differentiated cells with those in OS-differentiated-TGF-β1 cells revealed 566 common genes that were 
predicted to be regulated by TGF-β signalling and concurrently to be involved in OS-differentiation (Fig. 3C, 
Supplementary Table S3). Notably, we found that the selectively up-regulated genes in OS-differentiated-TGF-β1 
cells were enriched in categories of bone formation, such as ‘skeletal system development’ (58 genes), ‘ossifica-
tion’ (42 genes), and ‘osteoblast differentiation’ (23 genes) (Table 2). qRT-PCR results for selective up-regulated 
osteoblastic-related genes showed good concordance with microarray results (Fig. 3D).
Molecular phenotype of TGF-β1-induces adipocytic cells. Global gene expression profiling was 
conducted on cells treated with or without TGF-β1 (10 ng/ml) (day 3) in the presence of adipogenic induc-
tion medium. As shown in Fig. 4A, hierarchical clustering based on differentially expressed genes revealed clear 
separation of control samples treated with adipocyte induction medium alone (AD-differentiated) and those 
induced in presence of TGF-βl (AD-differentiated-TGF-β1). We identified 323 up- and 369 down-regulated genes 
in AD-differentiated-TGF-β1 compared to AD-differentiated cells (2.0 FC, p < 0.05; Supplementary Table S4, S5). 
Pathway analysis on the up-regulated genes in AD-differentiated-TGF-β1 treated samples revealed significant 
enrichment in several pathways related to adipogenesis, e.g. ‘adipogenesis’, ‘energy metabolism’, and ‘insulin sig-
nalling’ (Fig. 4B and Table 3). Comparing the list of the up-regulated genes in AD-differentiated cells and those 
in AD-differentiated-TGF-β1 cells revealed 1160 common genes that are predicted to be regulated by TGF-β 
Figure 3. Gene expression profiling on hBMSC induced into osteoblasts in the presence of TGF-β1.  
(A) Hierarchical clustering of human bone marrow stromal (skeletal) stem cells (hBMSC) induced into 
osteoblasts (OS) (day 3) in the presence or absence of TGF-βl. Each row represents one replica sample and each 
column represents a transcript. Expression level of each gene in a single sample is depicted according to the 
colour scale. (B) Pie chart illustrating the distribution of the top 13 pathway designations for the up-regulated 
genes in TGF-β1 treated cells during OS differentiation (C) Venn diagram depicting the overlap between the 
up-regulated genes during OS differentiation of hBMSCs and the upregulated genes in hBMSC induced to OS in 
presence of TGF-β1. (D) qRT-PCR validation of selected genes (TAGLN1, ACTA2, TPM1, and IGFL3).
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signalling and also involved in AD-differentiation (Fig. 4C, Supplementary Table S6). The selectively up-regulated 
genes in AD-differentiated-TGF-β1 were enriched in categories of ‘fat cell differentiation’, ‘fatty acid derivative 
biosynthesis process’, ‘fatty acid derivative metabolic process’, and ‘inositol lipid-mediated signalling’ (Table 4). 
qRT-PCR findings showed concordance with microarray data for a selected gene panel of the up regulated genes 
in TGF-β1 treated cells (Fig. 4D).
Identification of SERPINB2 as a TGF-β-responsive gene. Among the genes highly regulated by 
TGF-β1 treatment, we identified SERPINB2 (significantly down-regulated), ACTA2 (6 fold up-regulated), and 
TPM1 (4 fold up-regulated) (Fig. 5A). The specificity of TGF-β1 induction of SERPINB2 was demonstrated by 
SB-431542 treatment, which exerted an opposite effect (Fig. 5A). As shown in Fig. 5B, the enhanced OS and AD 
differentiation was associated with reduced expression of SERPINB2 during the course of differentiation, which 
reached a minimum (close to zero) during AD differentiation. Further, we interestingly observed by gene expres-
sion analysis that SERPINB2 gene is negatively regulated by TGF-β1 and positively upon inhibition of TGF-β1 
pathway by SB, and this finding was consistent both during osteoblast and adipocyte differentiation (Fig. s8)
Silencing of SERPINB2 in hBMSC promotes OS and AD differentiation. As osteoblastic and 
adipocytic differentiation was associated with reduced SERPINB2 expression, we employed a loss-of-function 
approach to assess the specific role of SERPINB2 in the differentiation processes. siRNA targeting of SERPINB2 
successfully down-regulated SERPINB2 gene expression (Fig. 5C) and protein expression as demonstrated by 
qRT-PCR and Western blot (Fig. 5D), respectively. No significant changes were observed in cell proliferation 
in SERPINB2-depleted cells as compared to siRNA-treated controls (Fig. 5E). The gene expression of ACTA2 
and TPM1, which are TGF-β responsive genes, was up-regulated in SERPINB2-depleted cells (Fig. 5F). 
Phosphorylated c-Jun and phosphorylated JNK proteins, which are modulators of TGF-β signalling pathways, 
were found to be induced in SERPINB2-depleted cells (Fig. 5G).
Notably, siRNA-mediated SERPINB2 inhibition led to enhanced OS and AD differentiation as evident by 
increased mineralised matrix formation (Fig. 6D), up-regulation of specific osteoblastic markers: ALPL, RUNX2, 
and OCN (Fig. 6E), increased numbers of mature adipocytes (Fig. 6F), and up-regulation of the adipogenic gene 
markers LPL and PPARG2 (Fig. 6G). These effects on hBMSCs differentiation were further confirmed by using 
primary human bone-marrow derived MSC, where similar results were obtained (Fig. s9).
SB-431542 rescued SERPINB2-siRNA-induced enhanced differentiation hMSC. To investigate 
the effect of induced expression of SERPINB2 on hBMSC differentiation, we conducted rescue experiment using 
SB-431542 to induce the endogenous SERPINB2. Treating SERPINB2-defecient cells with SB-431542 signifi-
cantly upregulated SERPINB2 gene expression (>6.0 FC; Fig. 7A). The gene expression of ACTA2 and TPM1, 
Endochondral 
Ossification
Matrix  
Metallo-proteinases
TGFB 
Signalling
WNT 
Signalling
MAPK 
Signalling
Focal 
Adhesion
Regulation of Actin 
Cytoskeleton
IGF1 MMP1 INHBA WNT7B IL1A COL11A1 ITGA1
IGF1R MMP2 NOG WNT11 TGFB2 COL3A1 GSN
IGF2 MMP11 THBS1 FZD2 ACVR1C COL4A1 NRAS
BMP6 MMP14 LEFTY1 FZD7 CASP9 COL4A2 IGF1
CDKN1C MMP24 SMAD7 DVL1 AKT3 COL4A4 PDGFA
TGFB2 MMP23B LIF CTNNB1 HSPB2 COL5A1 C11orf13
COL10A1 TIMP1 CTNNB1 TCF7 MAPK8 COL5A2 BDKRB1
C4ST1 TIMP2 RUNX3 TCF7L1 HSPA5 COL1A1 LIMK1
RUNX3 TIMP3 NKD1 MAPK8IP3 THBS1 PAK3
TIMP3 PPP2R1B MAP3K14 THBS2
PLAT PLAU NRAS TNC
PLAU PPARD ARHGAP5
ADAMTS4 AKT3
PAK3
MAPK8
IGF1R
ITGB1
ITGB3
ITGA11
IGF1
PDGFA
PDGFC
PGF
Table 1. Up-regulated genes involved in osteogenic-related pathways in TGF-β treated cells after osteogenic 
induction.
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Skeletal System Development Ossification Osteoblast Differentiation
Gene 
Symbol Gene Name Gene Symbol Gene Name Gene Symbol Gene Name
CYTL1 cytokine-like 1 GLI1 GLI family zinc finger 1 GLI1 GLI family zinc finger 1
HOXB2 homeobox B2 SEMA7A
semaphorin 7 A, GPI 
membrane anchor (John 
Milton Hagen blood group)
SEMA7A
semaphorin 7 A, GPI 
membrane anchor (John 
Milton Hagen blood 
group)
PLEKHA1
pleckstrin homology 
domain containing, family A 
(phosphoinositide binding 
specific) member 1
FBXL15 F-box and leucine-rich repeat protein 15 SNAI1 snail family zinc finger 1
CSRNP1 cysteine-serine-rich nuclear protein 1 SNAI1 snail family zinc finger 1 VCAN versican
SNAI1 snail family zinc finger 1 IGF1 insulin-like growth factor 1 (somatomedin C) IGF2
insulin-like growth factor 
2 (somatomedin A)
IGF1 insulin-like growth factor 1 (somatomedin C) VCAN versican TNC tenascin C
CHST11 carbohydrate (chondroitin 4) sulphotransferase 11 IGF2
insulin-like growth factor 2 
(somatomedin A) BMP6
bone morphogenetic 
protein 6
TIPARP TCDD-inducible poly(ADP-ribose) polymerase CDH11
cadherin 11, type 2, OS-
cadherin (osteoblast) ITGA11 integrin, alpha 11
IGF2 insulin-like growth factor 2 (somatomedin A) TNC tenascin C GLI2 GLI family zinc finger 2
CDH11 cadherin 11, type 2, OS-cadherin (osteoblast) BMP6
bone morphogenetic 
protein 6 LRRC17
leucine rich repeat 
containing 17
TGFBI transforming growth factor, beta-induced, 68 kDa ITGA11 integrin, alpha 11 CYP24A1
cytochrome P450, 
family 24, subfamily A, 
polypeptide 1
VDR vitamin D (1,25- dihydroxyvitamin D3) receptor GLI2 GLI family zinc finger 2 IGF2
insulin-like growth factor 
2 (somatomedin A)
HHIP hedgehog interacting protein COL10A1 collagen, type X, alpha 1 RSPO2 R-spondin 2
EBP emopamil binding protein (sterol isomerase) LRRC17
leucine rich repeat 
containing 17 SMO
smoothened, frizzled class 
receptor
BMP6 bone morphogenetic protein 6 CYP24A1
cytochrome P450, 
family 24, subfamily A, 
polypeptide 1
HDAC5 histone deacetylase 5
GLI2 GLI family zinc finger 2 MAPK8 mitogen-activated protein kinase 8 WNT11
wingless-type MMTV 
integration site family, 
member 11
COL10A1 collagen, type X, alpha 1 TUFT1 tuftelin 1 DLX5 distal-less homeobox 5
HOXC9 homeobox C9 TEK TEK tyrosine kinase, endothelial BMP2
bone morphogenetic 
protein 2
LRRC17 leucine rich repeat containing 17 IGF2 insulin-like growth factor 2 (somatomedin A) COL1A1 collagen, type I, alpha 1
DLX2 distal-less homeobox 2 RSPO2 R-spondin 2 LRRC17 leucine rich repeat containing 17
COL5A2 collagen, type V, alpha 2 SMO smoothened, frizzled class receptor CYP24A1
cytochrome P450, 
family 24, subfamily A, 
polypeptide 1
ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 HDAC5 histone deacetylase 5 NOG noggin
TEK TEK tyrosine kinase, endothelial PTGS2
prostaglandin-
endoperoxide synthase 
2 (prostaglandin 
G/H synthase and 
cyclooxygenase)
TMEM119 transmembrane protein 119
DLG1 discs, large homolog 1 (Drosophila) WNT11
wingless-type MMTV 
integration site family, 
member 11
IGF2 insulin-like growth factor 2 (somatomedin A) GNAS GNAS complex locus
RSPO2 R-spondin 2 MMP14 matrix metallopeptidase 14 (membrane-inserted)
EXTL1 exostosin-like glycosyltransferase 1 ASPN asporin
LEPRE1 leucine proline-enriched proteoglycan (leprecan) 1 CDH11
cadherin 11, type 2, OS-
cadherin (osteoblast)
SMO smoothened, frizzled class receptor DLX5 distal-less homeobox 5
Continued
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which are TGFB responsive genes, were up-regulated in SERPINB2-depleted cells. Enhanced OS and AD dif-
ferentiation in SERPINB2-depleted cells were significantly reversed in the presence of SB-431542 as shown by 
reduced mineralized matrix formation (Fig. 7B) and down-regulation of osteoblastic gene markers: OCN, OPN, 
COL1a1, and BMP4 (Fig. 7C), and reduced number of mature adipocytes (Fig. 7D) as well as down-regulation of 
adipocytic gene markers: LPL and PPARG2 (Fig. 7E).
Molecular phenotype of SERPINB2-depleted hBMSCs. Global gene expression profiling was 
conducted on SERPINB2-depleted hBMSCs and compared with control scramble siRNA transfected cells. 
Hierarchical clustering based on differentially expressed genes revealed clear separation of control cells from 
SERPINB2-siRNA transfected cells (Fig. 8A). We identified 836 up-regulated and 670 down-regulated genes in 
Skeletal System Development Ossification Osteoblast Differentiation
Gene 
Symbol Gene Name Gene Symbol Gene Name Gene Symbol Gene Name
THBS1 thrombospondin 1 MMP2
matrix metallopeptidase 
2 (gelatinase A, 72 kDa 
gelatinase, 72 kDa type IV 
collagenase)
PBX1 pre-B-cell leukaemia homeobox 1 BMP2 bone morphogenetic protein 2
WNT11 wingless-type MMTV integration site family, member 11 MAPK8
mitogen-activated protein 
kinase 8
GNAS GNAS complex locus SLC26A2
solute carrier family 
26 (anion exchanger), 
member 2
TGFB2 transforming growth factor, beta 2 FOXS1 forkhead box S1
SOX4 SRY (sex determining region Y)-box 4 COL1A1 collagen, type I, alpha 1
COL3A1 collagen, type III, alpha 1 FSTL3 follistatin-like 3 (secreted glycoprotein)
RUNX3 runt-related transcription factor 3 LRRC17 leucine rich repeat containing 17
CSRNP1 cysteine-serine-rich nuclear protein 1 CYP24A1
cytochrome P450, 
family 24, subfamily A, 
polypeptide 1
CDH11 cadherin 11, type 2, OS-cadherin (osteoblast) SPARC
secreted protein, acidic, 
cysteine-rich (osteonectin)
DLX5 distal-less homeobox 5 PDLIM7 PDZ and LIM domain 7 (enigma)
MMP2
matrix metallopeptidase 2 
(gelatinase A, 72 kDa gelatinase, 
72 kDa type IV collagenase)
NOG noggin
BMP2 bone morphogenetic protein 2 TMEM119 transmembrane protein 119
CYTL1 cytokine-like 1
WNT7B wingless-type MMTV integration site family, member 7B
COL11 A1 collagen, type XI, alpha 1
FOXS1 forkhead box S1
COL1A1 collagen, type I, alpha 1
SGPL1 sphingosine-1-phosphate lyase 1
LRRC17 leucine rich repeat containing 17
SUFU suppressor of fused homolog (Drosophila)
HES7 hes family bHLH transcription factor 7
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
NOG noggin
THBS1 thrombospondin 1
MATN3 matrilin 3
CADM1 cell adhesion molecule 1
POSTN periostin, osteoblast specific factor
CADM1 cell adhesion molecule 1
Table 2. Up-regulated biological processes and related genes in TGF-β1 treated cells during osteogenesis using 
GO analysis.
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SERPINB2-depleted cells compared to control cells (2.0 FC, p < 0.05; Supplementary Table S7). Pathway analy-
sis performed on the up-regulated genes revealed significant enrichment in several genetic pathways related to 
‘endochondral ossification’, ‘adipogenesis’, ‘TGF-β signalling’, ‘WNT signalling’, and ‘MAPK signalling’ pathways 
(Fig. 8B). Good concordance was observed between microarray and qRT-PCR results for a selected regulated 
gene panel (Fig. 8C).
Discussion
The TGFβ signalling pathway plays a regulatory role in hBMSC biology; however, the molecular details of its 
action have not been elucidated. In the present study, we investigated the role of TGF-β1 during OS and AD dif-
ferentiation of hBMSC and described a novel TGF-β1-responsive gene in hBMSC: SERPINB2.
We observed differences in the biological effects of TGF-β1 on hBMSC differentiation dependent on the 
temporal exposure of the cells. Continuous treatment with TGF-β1 was more effective in enhancing OS differ-
entiation, whereas a single treatment with TGF-β1 during the commitment phase preferentially enhanced AD 
differentiation. However, these effects were quantitative rather than qualitative and suggest that TGF-β1 is impor-
tant for both OS and AD differentiation. Moreover, the specificity of the effects was demonstrated by using the 
TGF-β receptor kinase inhibitor SB-431542.
We observed that TGF-β1 promoted OS differentiation and up-regulation of osteoblastic genes (ALPL, 
RUNX2, and OSC). Previous studies have also demonstrated that TGF-β1 regulates the differentiation of 
osteo-progenitor cells7–10, although the direction of such regulation has been disputed. For example, some studies 
reported the inhibition of OS differentiation in vitro by TGF-β18, 11. In contrast, it has also been reported that 
TGF-β1 stimulates bone matrix deposition and bone cell replication12, whereas inhibition of TGF-β1 signalling 
was shown to suppress OS differentiation13. Despite these contradictory data, most studies support a model in 
which TGF-β1 promotes bone formation by recruiting OS progenitors and inducing the formation of bone matrix 
at early stages of OS differentiation. However, at later stages of OS differentiation, TGF-β1 appears to inhibit OS 
differentiation and mineralisation11, 14, 15, probably secondary to regulation by other growth factors e.g. bone 
morphogenic proteins (BMPs)16, 17. The reported findings of TGF-β1 enhancing the expression of RUNX2 in 
Figure 4. Gene expression profiling of hBMSC induced into adipocytes in the presence of TGF-β1. (A) 
Hierarchical clustering of human bone marrow stromal (skeletal) stem cells (hBMSC) induced into adipocytes 
(AD) (day 3) in the presence or absence of TGF-βl. Each row represents one replica sample and each column 
represents a transcript. Expression level of each gene in a single sample is depicted according to the colour 
scale. (B) Pie chart illustrating the distribution of the top 13 pathway designations for the up-regulated genes 
in TGF-β1 treated cells during adipogenesis. (C) Venn diagram depicting the overlap between the up-regulated 
genes during AD induction of hBMSC and the upregulated genes in hBMSC induced to AD in presence of TGF-
β1. (D) qRT-PCR validation of selected genes from the microarray data (SULF1, TPM1, MYL9, ACTA2, and 
IGFL3).
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combination with BMPs during the early stage of OS differentiation18 and its induction of SMAD2 at later stages 
of OS differentiation that, interacts with RUNX2 causing suppression of the expression of RUNX2 itself and of a 
consequently other osteoblastic genes including ALPL, collagen type 1, and oxidosqualene cyclase (OSC) by an 
auto-regulatory feedback mechanism15, 19–23, may explain this dual role of TGF-β1 in OS differentiation. These 
findings suggest that TGF-β1 effects are dependent on the differentiation stage of the target cells and/or presence 
of other interacting factors.
Although many studies have reported inhibitory effect of TGF-β1 on adipogenesis, some reports have demon-
strated a pro-adipogenic effect of TGF-β124, 25, which is more consistent with the observed TGF-β1 enhance-
ment of bone marrow adipocyte formation observed in the current study. For example, the treatment of mouse 
NIH/3T3-L1 fibroblasts with TGF-β1 significantly suppressed mature adipocyte formation, irrespective of 
whether the treatment constituted a single dose at the initiation of differentiation or a continuous exposure26. 
Continuous exposure to TGF-β1 during adipogenic induction, inhibited adipogenic differentiation of mesenchy-
mal cells, through repression of the function of the key adipogenic transcription factors C/EBPβ and C/EBPδ27. 
Furthermore, it was demonstrated that continuous exposure to TGF-β inhibited adipogenesis due to significant 
reduction in TGF-β receptor levels, which was mediated through SMAD2 and SMAD328. In contrast, an early 
study of brown adipocytes in rat showed up-regulation of the expression of lipogenic enzymes upon treatment 
with 100 pM TGF-β125. TGF-β1-induced inhibition models used either a low single dose (approximately 2 ng/ml) 
at the time of differentiation induction or a continuous dose (ranging from 0.2–10 ng/ml). Therefore, the discrep-
ancies observed in different studies might reflect different cell types employed and experimental setups.
Among the genes highly regulated by TGF-β1 treatment, we identified SERPINB2 as a novel gene supressed by 
TGF-β induction in hBMSC. The physiological role of SERPINB2 in bone biology has not previously been inves-
tigated. Plasminogen activator inhibitor-2 (SERPINB2), also called PAI-2, is a member of the Ov-serpin family of 
serine protease inhibitors29. It is expressed in particular in monocytes/macrophages, as well as in a wide range of 
other hematopoietic and non-hematopoietic cells30. SERPINB2 has been shown to bind several intracellular and 
extracellular proteins, indicating physiological function in both intracellular and extracellular compartments31. 
SERPINB2 functions as a coagulation factor that inactivates urokinase and as a tissue-type plasminogen activator 
in the extracellular space and on the cell surface29, 32. SERPINB2 is highly expressed in pregnancy, infection and 
inflammation32. Interestingly, SERPINB2 was downregulated in co-cultured hMSC with U87-MG (glioblastoma 
multiformae (GBM) cell line) suggesting a role in stroma-cancer cell interaction that needs to be clarified33. We 
have clearly shown that SERPINB2 is up-regulated when TGF-βpathway is blocked by SB which lead to inhibition 
of differention hBMSCs and the opposite was seen when we stimulated TGF-β pathway see Fig. 7.
In conclusion, our results provide additional details to the role of TGF-β intracellular signalling pathway in OS 
and AD differentiation of hBMSC and identify SERPINB2 as a negative regulator of these effects Fig. 8D illustrates 
our current working model for the role of TGF-β on hBMSC through the suppression of SERPINB2 gene and we 
provide a possible list of down-stream targets ACTA2, TPM1, c-JUN, and JNK. Future studies are required to 
clarify the mechanistic role of SERPINB2 in vivo skeletal biology. SERPINB2 may also serve as a target to develop 
strategies for regulating bone mass and bone marrow fat.
Methods
Cell Culture. As a model for primary human bone marrow MSCs, the hMSC-TERT cell line was established 
from normal human bone marrow MSCs though overexpression of the human telomerase reverse transcriptase 
gene (hTERT)34. hMSC-TERT cells have been extensively characterised as exhibiting a similar cellular and molec-
ular phenotype to primary hBMSCs33. In the current study, we employed a sub-clone derived from hMSC-TERT 
termed hMSC-TERT-CL1, which has been characterised previously35. For simplicity, we refer to this line as 
hBMSC throughout the manuscript.
Probe Name Gene Name
Gene 
Symbol
FC ([AD + TGFB1] 
vs. [AD])
A_23_P53891 Kruppel-like factor 5 (intestinal) KLF5 6.4302254
A_23_P13907 insulin-like growth factor 1 (somatomedin C) IGF1 5.5686526
A_23_P46936 early growth response 2 EGR2 3.4646597
A_23_P18447 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha PPARGC1A 3.062086
A_24_P22079 forkhead box O1 FOXO1 2.6298373
A_33_P3302295 forkhead box C2 (MFH-1, mesenchyme forkhead 1) FOXC2 2.3352392
A_23_P137381
inhibitor of DNA binding 3, 
dominant negative helix-loop-helix 
protein
ID3 2.3178163
A_33_P3237150 bone morphogenetic protein 2 BMP2 2.2145567
A_24_P38276 frizzled class receptor 1 FZD1 2.089059
A_24_P154037 insulin receptor substrate 2 IRS2 2.0130024
A_23_P211007 nuclear receptor interacting protein 1 NRIP1 2.0108652
Table 3. Up regulated genes involved in adipogenesis pathway in TGF-β1 treated cells after adipogenic 
induction.
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The cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 4500 mg/l D-glucose, 
4 mM L-glutamine, 110 mg/l sodium pyruvate, 10% foetal bovine serum (FBS), 1× penicillin-streptomycin 
(Pen-strep), and non-essential amino acids (all purchased from Gibco-Invitrogen, Carlsbad, CA).
In vitro OS differentiation. Cells were grown in standard DMEM growth medium in 6-well plates at 
0.3 × 106 cells/ml. When 70–80% confluence was reached, test cells were cultured in DMEM supplemented with 
OS induction mixture containing 10% FBS, 1% Pen-strep, 50 μg/ml L-ascorbic acid (Wako Chemicals, Neuss, 
Germany), 10 mM β-glycerophosphate (Sigma, St. Louis, MO), and 10 nM calcitriol (1α, 25-dihydroxyvitamin 
D3; Sigma), and 10 nM dexamethasone (Sigma). The media were replaced 3 times per week. Cells cultured in 
standard culture medium were considered as the negative control.
For dose response experiments, cells were seeded and treated at D -2 with 10 ng/ml TGF-β1 for 2 days com-
mitment stage, then differentiation stage was initiated by adding osteoblastic induction medium at D0, while 
TGF-β1 treatment was continued till day 7 in TGF-β -continuous treated cells.
In vitro AD differentiation. Cells were grown in standard DMEM growth medium in 6-well plates at 
0.3 × 106 cells/ml. At 90–100% confluence, cells were switched to DMEM supplemented with adipogenic induc-
tion mixture containing 10% FBS, 10% horse serum (Sigma), 1% Pen-strep, 100 nM dexamethasone, 0.45 mM 
isobutyl methyl xanthine36 (Sigma)], 3 μg/ml insulin (Sigma), and 1 μM rosiglitazone37 (Novo Nordisk, Bagsvaerd, 
Denmark). The media were replaced 3 times per week. Cells cultured in standard culture medium were consid-
ered as the negative control. For dose response experiments, cells were seeded and treated at D -2 with 10 ng/ml 
TGF-β1 for 2 days commitment stage, then differentiation stage was initiated by adding adipocytic induction 
medium at D0, while TGF-β1 treatment was continued till day 7 in TGF-β -continuous treated cells.
Cytochemical staining. Alizarin Red S staining for mineralised matrix. The cell layer was washed with 
phosphate buffered saline (PBS) and then fixed with 4% paraformaldehyde for 15 min at room temperature. After 
removing the fixative, the cell layer was rinsed in distilled water 3 times and stained using a 2% Alizarin Red S 
Staining Kit (Cat. No. 0223, ScienCell, Research Laboratories, Carlsbad, CA) for 20–30 min at room temperature. 
Excess dye was washed off with water 3–5 times; subsequently, the stained cells were kept in water to prevent 
drying out. Images were acquired using an inverted Zeiss microscope (Thornwood, NY). For quantification of 
Alizarin Red S staining, plates were air-dried and then the Alizarin Red S dye was eluted in 800 µl acetic acid 
incubated in each well for 30 min at room temperature as previously described38 and measured using an Epoch 
spectrophotometer (Bio-Tek, Winooski, VT) at 405 nm.
OsteoImage mineralisation assay. The in vitro-formed mineralised matrix was quantified using the OsteoImage 
Mineralization Assay Kit (Cat. No. PA-1503, LONZA, Allendale, NJ). Culture medium was removed and cells 
were washed once with PBS, then fixed with 70% cold ethanol for 20 min. An appropriate amount as recom-
mended by the manufacturer of diluted staining reagent was added and plates were incubated in the dark for 
Fat Cell Differentiation Fatty Acid Derivative Biosynthesis Process Fatty Acid Derivative Metabolic Process
Inositol Lipid-Mediated 
Signalling
Gene 
Symbol Gene Name
Gene 
Symbol Gene Name
Gene 
Symbol Gene Name
Gene 
Symbol Gene Name
RGS2 regulator of G-protein signalling 2, 24 kDa EDN1 endothelin 1 EDN1 endothelin 1 IGF1
insulin-like 
growth factor 1 
(somatomedin C)
INHBB inhibin, beta B PTGS1
prostaglandin-endoperoxide synthase 
1 (prostaglandin G/H synthase and 
cyclooxygenase)
PTGS1
prostaglandin-endoperoxide synthase 
1 (prostaglandin G/H synthase and 
cyclooxygenase)
FGF1 fibroblast growth factor 1 (acidic)
PPARGC1A
peroxisome proliferator-
activated receptor 
gamma, coactivator 1 
alpha
PTGS2
prostaglandin-endoperoxide synthase 
2 (prostaglandin G/H synthase and 
cyclooxygenase)
ALOX15B arachidonate 15-lipoxygenase, type B EDN1 endothelin 1
RUNX1T1
runt-related transcription 
factor 1; translocated to, 
1 (cyclin D-related)
PTGS1
prostaglandin-endoperoxide synthase 
1 (prostaglandin G/H synthase and 
cyclooxygenase)
PTGS2
prostaglandin-endoperoxide synthase 
2 (prostaglandin G/H synthase and 
cyclooxygenase)
NPR3 natriuretic peptide receptor 3
EGR2 early growth response 2 GGT5 gamma-glutamyltransferase 5 PTGS1
prostaglandin-endoperoxide synthase 
1 (prostaglandin G/H synthase and 
cyclooxygenase)
NRG1 neuregulin 1
FOXO1 forkhead box O1 C9orf3 chromosome 9 open reading frame 3 GGT5 gamma-glutamyltransferase 5 IRS2 insulin receptor substrate 2
PTGS2
prostaglandin-
endoperoxide synthase 
2 (prostaglandin 
G/H synthase and 
cyclooxygenase)
C9orf3 chromosome 9 open reading frame 3 FOXO1 forkhead box O1
FGF7 fibroblast growth factor 7
Table 4. Up-regulated biological processes and related genes in TGF-β1 treated cells during adipogenesis using 
GO analysis.
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30 min at room temperature. Cells were washed and staining intensity was assessed using a fluorescent plate 
reader at 492/520 excitation emission wavelengths.
Oil red-O staining for lipid droplets. Mature adipocytes filled with cytoplasmic lipid droplets were visualised by 
staining with Oil Red-O. After washing with PBS, the cells were fixed in 4% formaldehyde for 10 min at room 
temperature, then rinsed once with 3% isopropanol and stained for 1 h at room temperature using filtered Oil 
Red-O staining solution (prepared by dissolving 0.5 g Oil red-O powder in 60% isopropanol). To quantify the 
mature adipocytes formed, Oil Red O stain was eluted by adding 100% isopropanol to each well and absorbance 
was measured using an Epoch spectrophotometer at 510 nm.
Nile red fluorescence determination and quantification of mature adipocytes. Stock solution of Nile red (1 mg/ml) 
in DMSO was prepared and stored at −20 °C protected from light. Staining was performed after fixing the cells 
using 4% paraformaldehyde (Sigma) for 15 min at room temperature, then washed with PBS. The dye was added 
directly to the cells (5 μg/ml in PBS) and the cells were incubated for 10 min at room temperature. Fluorescent 
signal was measured with a SpectraMax/M5 fluorescence spectrophotometer plate reader (Molecular Devices 
Co., Sunnyvale, CA) using the bottom well-scan mode where nine readings were taken per well using excitation 
485 nm and emission 572 nm spectra.
Figure 5. SERPINB2 is a TGF-β-target gene that is suppressed in human bone marrow stromal (skeletal) stem 
cells (hBMSC) during osteoblast and adipocyte differentiation. (A) qRT-PCR performed for TGF-β responsive 
genes: SERPINB2, ACTA2, and TPM2 for controls (CNT), as well as for cells treated with: SB-431542 (SB) 
and TGF-β1. Expression of each target gene was normalised to GAPDH. Data are shown as the SD of three 
independent experiments (B) qRT-PCR showing time course of SERPINB2 expression between day (D) 0, D1, 
D3, D5, and D7 for cells induced with either osteoblast (OS) or adipocyte (AD) induction medium.  
(C) qRT-PCR of SERPINB2 mRNA expression on day 3 post transfection with SERPINB2-specific or scrambled 
control siRNA. Data are presented as fold change mRNA expression ± SD from three independent experiments 
(D) Western blot analysis of SERPINB2 in SERPINB2-siRNA-depleted cells compared to scramble-siRNA 
transfected control cells (upper panel). B-Actin (ACTB, lower panel) was used as a loading control. (E) Cell 
viability measured using Alamar blue assay for hBMSCs on days 2, 4, 6, and 8 post transfection with scrambled 
(SCR) or SERPINB2-specific siRNA. (F) qRT-PCR for ACTA2, and TPM1 expression on day 3 post transfection 
with SERPINB2-specific or scramble (SCR) siRNA, in the presence or absence of SB-431542. Data are presented 
as mean fold change in mRNA expression ± SD, from three independent experiments. (G) Western blot analysis 
for P-c-JUN and P-JNK in SERPINB2-depleted cells compared to scramble transfected control cells (upper 
panel), whereas B-Actin (ACTB, lower panel) was used as a loading control. ***p < 0.005.
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Real time qRT-PCR. Total RNA was extracted from differentiating cells either treated or not treated (con-
trol samples) with single dose of TGF-β1 at D5 of induction using a PureLink RNA mini isolation kit (Cat No: 
12183018 A, Ambion by Life Technologies, Austin, TX) as recommended by the manufacturer. Total RNA was 
quantified using a Nanodrop spectrophotometer (Nanodrop 2000, Thermo Scientific, Waltham, MA). cDNA 
was synthesised from 1 μg of the RNA samples using a High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA) using a Labnet, Multigene thermocycler (Edison, NJ) according to the manufacturer’s 
instructions. Relative levels of mRNA were determined from cDNA using real time PCR (Applied Biosystem-Real 
Time PCR Detection System) with a Power SYBR Green PCR kit (Applied Biosystems, UK), or with the TaqMan 
Universal master Mix II, no UNG (Applied Biosystems, Foster City, CA) according to the manufacturer’s instruc-
tions. Following normalisation to the reference gene GAPDH, quantification of gene expression was carried out 
using a comparative Ct method where ΔCT is the difference between the CT values of the target and reference gene. 
Primers (Supplementary Tables S8 and S9) were either obtained directly from Applied Biosystems (Foster City, CA) 
as TaqMan primers or were synthesised by Life Technologies based on previously published primer sequences.
DNA microarray global gene expression profiling. Total RNA was extracted from differentiating cells 
either treated or not treated (control samples) with single dose of TGF-β1 at D5 of induction using the PureLink 
RNA mini isolation kit as recommended by the manufacturer. Then, 150 ng total RNA was labelled and hybrid-
ised to the Agilent Human SurePrint G3 Human GE 8 × 60 k microarray chip (Agilent Technologies, Santa Clara, 
CA). All microarray experiments were conducted at the Microarray Core Facility (Stem Cell Unit, King Saud 
Figure 6. Down-regulation of SERPINB2 promotes osteoblastic and adipocytic differentiation of human bone 
marrow stromal (skeletal) stem cells (hBMSC) (A) mineralised matrix deposition was assessed using Alizarin 
Red S staining (lower panel). Quantification of mineralised matrix formation under control (CNT), cells 
transfected with either transfection with SERPINB2-specific (SERBIN siRNA) or scramble (SCR) siRNA (upper 
panel). Data are presented as relative mineralisation ± SD from three independent experiments. (B) qRT-PCR 
quantification of the osteoblastic markers (ALPL, RUNX2, and OCN) on day 7 under the indicated treatment 
conditions, OS (osteoblast differentiation). Expression of each target gene was normalised to GAPDH. Data 
are presented as the means ± SD from three independent experiments, hBMSCs under different experimental 
conditions were induced into adipocytes for 5 days and subsequently stained using Oil Red O (C, lower panel). 
Data are shown as microscopic images (40×). Nile red stain quantification is shown in the upper panel. Data 
are presented as mean relative Nile red staining intensity ± SD from three independent experiments. (D) qRT-
PCR quantification for the adipogenic markers (PPARG2 and LPL) for hBMSCs under different treatment 
conditions. AD (adipocyte differentiation). Expression of each target gene was normalised to GAPDH. Data 
are presented as fold change in mRNA expression ± SD from three independent experiments. *p < 0.05; 
**p < 0.005, ***p < 0.0005.
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University College of Medicine). Normalisation and data analyses were conducted using GeneSpring GX software 
(Agilent Technologies). Pathway analysis was conducted using the Single Experiment Pathway analysis feature in 
GeneSpring 12.0 (Agilent Technologies). A two-fold cut off with p < 0.05 was used.
Western blotting. Whole cell lysates were prepared as previously described38. Soluble proteins were analysed 
by immunoblotting with antibodies anti-SERPINB2, anti-P-c Jun, and anti-P-UNK (ThermoFisher Scientific, 
diluted 1:5000), and anti-β-ACTIN (Sigma, A3854, diluted 1:10,000). Reactivity was detected with horseradish 
peroxidase-conjugated secondary antibodies (Santa-Cruz Biotechnology, Dallas, TX) and Clarity western ECL 
substrate (Bio-Rad Laboratories, Berkeley, CA) for chemiluminescence using a C-Digit Blot Scanner (LI-COR, 
Lincoln, NE).
siRNA transfection. For transfection, hBMSC cells in logarithmic growth phase were reverse-transfected 
with Silencer Select Pre-designed SERPINB2-siRNA (25 nM) (Ambion ID: s10016, s10017, and s10018, Cat. no. 
4392420, Thermo Fisher Scientific Life Sciences) using Lipofectamine RNAiMAX Reagent (Invitrogen) plus 
serum-free Opti-MEM® I medium (Thermo Fisher Scientific Life Sciences) as per the manufacturer recommen-
dation. On day 3 of transfection, the cells were induced into OSs or ADs for an additional 5 days.
Figure 7. Inhibition of TGFB signaling reversed the enhanced osteoblastic and adipocytic differentiation 
observed in SERPINB2-depleted human bone marrow stromal (skeletal) stem cells (hBMSC). (A) q-RT-PCR 
for SERPINB2, ACTA2, and TPM1 expression on day 3 post transfection with SERPINB2-specific-siRNA or 
Scramble siRNA (SCR), in the presence or absence of SB-431542 (SB). Data are presented as mean fold change 
in mRNA expression ± SD, from three independent experiments. (B) Mineralized matrix deposition was 
determined by Alizarin Red S staining presented as microscopic images (magnification 40X) of stained wells 
(left panel). Quantification of mineralized matrix formation under different treatment conditions is presented 
in the right panel, OS (osteoblast differentiation). Data are presented as mean relative mineralization ± SD 
from three independent experiments; (C) qRT-PCR for OSN, OSP, COL1A1 and BMP4 osteoblastic markers. 
Expression of each target gene was normalized to GAPDH. Data are presented as mean ± SD from three 
independent experiments. Cells were induced into adipocyte (AD) for 5 days in the presence or absence of SB-
431542 (SB) and stained using Oil Red O (D) as shown in the representative microscopic images (left panel) 
as well as Nile Red stain quantification (right panel) under different experimental conditions: AD induced of 
scramble-siRNA (CNT), and adipo-induced SERPINB2-siRNA-depleted cells. (E) qRT-PCR quantification 
for PPARG2, and LPL adipocytic markers under the indicated treatments. Expression of each target gene was 
normalized to GAPDH. Data are presented as mean ± SD from three independent experiments. n = 6.  
**p < 0.005, ***P < 0.0005.
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Statistical analysis. All results presented are given as the means ± standard deviation (SD) of at least 3 
independent experiments, unless indicated otherwise. A student’s t-test was used for testing differences between 
groups. p-values < 0.05 were considered statistically significant.
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